tbuckley/cabot-search huggingface dataset:
SAT0495 Assessment of Plantar Pressure Distribution During Walking after Forefoot Surgery in Patients with Rheumatoid Arthritis
Authors: K. Ebina, K. Shi, T. Tomita, Y. Kunugiza, M. Hirao, J. Hashimoto, H. Yoshikawa
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In rheumatoid arthritis (RA) patients, (1) hallux MTP-joint arthroplasty (Swanson implant)+2<sup>nd</sup>-5<sup>th</sup> toes metatarsal head resection arthroplasty and (2) hallux Scarf osteotomy+2-5<sup>th</sup> toes metatarsal shortening osteotomy are both standard methods. <h3>Objectives</h3> The objective of this study is to investigate the unknown difference of operation (1) and (2) on plantar pressure distribution during walking. <h3>Methods</h3> 3-feet of healthy volunteer (3 male / age 44.7y / body mass index [BMI] 20.2kg/m<sup>2</sup>), 12 feet of RA patients with operation (1) (3 male 9 female / age 62.4y / postoperation duration 6.8y / standing leg-heel angle [S-LHA]1.3° / BMI 20.8kg/m<sup>2</sup>), and 13 feet of RA patients with operation (2) (13 female / age 62.0y / postoperation duration 3.9y / S-LHA 0.5° / BMI 20.4kg/m<sup>2</sup>) were enrolled. Average plantar pressure during walking through 2<sup>nd</sup> to 6<sup>th</sup> steps was assessed by F-SCANⅡ® (Tekscan Inc.). <h3>Results</h3> There was no significant difference in age, postoperation duration, S-LHA, and BMI between group (1) and (2). Plantar pressure distribution of hallux MTP-joints was 13.1% in healthy volunteer / operation (1) 7.0% / operation (2) 10.6%, and was significantly small in operation (1) compared to healthy volunteer (P&lt;0.001) and to operation (2) (P&lt;0.01). On the other hand, Plantar pressure distribution of 2<sup>nd</sup>-5<sup>th</sup> toes MTP-joints was 19.2% in healthy volunteer / operation (1) 20.4% / operation (2) 12.4%, and was significantly small in operation (2) compared to healthy volunteer and to operation (1) (P&lt;0.01). <h3>Image/graph</h3> <h3>Conclusions</h3> Swanson implant arthroplasty of hallux MTP-joints may decrease plantar pressure distribution of MTP-joints compared to hallux Scarf osteotomy, and 2-5<sup>th</sup> toes metatarsal head resection arthroplasty may increase plantar pressure distribution of MTP-joints compared to 2-5<sup>th</sup> toes metatarsal shortening osteotomy. <h3>Disclosure of Interest</h3> None Declared
Introduction of the Early Palliative Care Using Central Venous Access Port Device (Cv Port) in Patients with Lung Cancer
Authors: T. Hirashima, T. Tsumori, W. Shinzaki, T. Yamadori, H. Suzuki, K. Shimura, K. Iwata, H. Hino, H. Shigeoka, S. Goya
Journal: Annals of Oncology (2013)
Abstract 3479: Claudin-14: A novel regulator of angiogenesis
Authors: Marianne Baker, Stephen D. Robinson, Kairbaan Hodivala-Dilke, Tamar Ben-Yosef
Journal: Cancer Research (2011)

Abstract Angiogenesis, the formation of new blood vessels from pre-existing ones, is vital for tumor growth and spread. A better understanding of angiogenic processes, particularly cell-cell adhesion, is required for the development of effective anti-angiogenic drugs. Claudin-14 (Cldn14) is a component of Tight Junctions (TJ) and its function in angiogenesis is not yet known. Other TJ molecules such as JAMs are known to be involved in angiogenesis; for example, we have identified a novel dosage-dependent role for JAM-B in the regulation of angiogenesis in the context of trisomy of human chromosome 21 (Hsa21) genes (Reynolds et al. Nature 2010); Cldn14 is also present on Hsa21. Therefore we hypothesise that Cldn14 may also play a role in the regulation of angiogenesis. Here we show that depletion of Cldn14 enhances VEGF-stimulated angiogenesis in the ex vivo aortic ring assay and increases primary mouse lung endothelial cell proliferation via changes in downstream signalling. Viable Cldn14 knockout mice exhibit normal vasculature in unchallenged organs, suggesting that the effect may be specific to pathological states. These data reveal novel regulatory roles for Cldn14 and future work will characterise further the functions of Cldn14 in angiogenesis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3479. doi:10.1158/1538-7445.AM2011-3479
Phase II trial of gemcitabine-carboplatin-paclitaxel (GCP) as neo-adjuvant chemotherapy for operable non-small cell lung cancer (NSCLC)
Authors: R. P. Abratt, J. S. Lee, J. Y. Han, C. M. Tsai, M. Boyer, T. Mok, S. W. Kim, J. S. Lee, A. J. M. Brnabic, M. Lehnert
Journal: Journal of Clinical Oncology (2005)

7260 Background: Randomized phase III trials suggest that neo-adjuvant cisplatin-based chemotherapy prior to surgery may improve survival in patients (pts) with operable NSCLC. The aim of this open-label single-arm phase II study (B9E-MC-S179) is to evaluate the efficacy, feasibility and safety of the GCP combination as neo-adjuvant chemotherapy in pts with operable stage NSCLC. Methods: Major eligibility criteria included histologic or cytologic diagnosis of NSCLC; Stage IB, II or IIIA disease; tumor amenable to curative surgical resection; no prior tumor therapy; ECOG performance status 0 or 1; and written informed consent. Pts were given 3 cycles of chemotherapy followed by tumor resection. Each 21-day cycle consisted of gemcitabine 1000 mg/m2 on days 1 and 8, carboplatin AUC 5 on day 1 and paclitaxel 175 mg/m2 on day 1. The primary endpoint was response rate and secondary endpoints included safety and time-to-event variables. Results: The results from this interim analysis include all endpoints except time-to-event variables. Forty-four pts were enrolled: 39 males, 5 females; mean age 56.4 yr, range 37–67 yr; 18% Stage IB, 16% Stage II, 66% Stage IIIA. All 44 pts received 3 cycles of treatment: 33 pts had a partial response to chemotherapy for a response rate of 75% (95% CI: 60–87%). 3 pts did not undergo surgery (1 pt had brain metastases discovered, 1 pt died from the study disease and the tumor of 1 pt was no longer amenable to surgery). 36 pts had a complete tumor resection, 5 of whom had no viable tumor cells in the resected tumor on histological examination. Toxicity caused a reduction or delay in gemcitabine for 32 pts (73%), in carboplatin for 12 pts (27%) and in paclitaxel for 11 pts (25%). Grade 3/4 hematological toxicity was reported by 37 pts (84%), most commonly neutropenia (34 pts, 77%) and thrombocytopenia (11 pts, 25%). Other toxicities included grade 3/4 anemia (4 pts), increased alanine aminotransferase (3), febrile neutropenia (1), bleeding (1), vomiting (1), rash (1) and grade 2 alopecia (35). Conclusions: Neo-adjuvant GCP chemotherapy appears to be safe and feasible for operable NSCLC and preliminary efficacy data appear promising. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly AstraZeneca, Novartis Eli Lilly AstraZeneca, Eli Lilly, Pfizer Eli Lilly Korea, SK Pharma Korea AstraZeneca, Eli Lilly, Novartis, Pfizer
Abstract 4362: Plk1 is overexpressed in retinoblastoma and its inhibition by siRNA or small-molecule inhibitor results in growth arrest and apoptosis
Authors: Andrew Berglund, Clifton L. Dalgard
Journal: Cancer Research (2010)

Abstract Retinoblastoma (RB) is a pediatric cancer of the retina where current chemotherapeutic regimens are broad spectrum with significant side effects. Molecular target-based approaches for RB therapy are absent and may be rational for this disease. We performed a siRNA library screen for growth inhibition of human Y79 RB cells. Knockdown of Plk1 or AURKA (but not other mitotic regulatory factors) lead to greater than 90% cell growth inhibition and prompted further investigation. We determined Plk1 expression in retinoblastoma and normal retina tissue by immunohistochemistry. We also determined the effects of siRNA-mediated Plk1 knockdown and small molecule-mediated Plk1 inhibition on Y79 and Weri-Rb1 cell growth using a tetrazolium dye-based assay. Effects on proliferation and cell cycle distribution were determined by flow cytometric analysis of EdU incorporation and DNA content. Activation of DNA damage response and apoptosis was determined by western blot analysis of phospho-H2AX, cleaved caspase-3, and PARP. We observed moderate and high Plk1 protein expression in several human retinoblastoma tumor samples as compared to minimal or low expression found in normal retinal tissue. Increased Plk1 expression was observed in RB cell lines as compared to normal retina cells. 10 nM Plk1 siRNA and 30 nM BI-2536 potently inhibited Y79 and Weri-Rb1 cell growth and significantly decreased cell viability. A decrease in S phase EdU incorporation and proliferation and an increase in G1 phase population was observed in flow cytometric analysis of Plk1 inhibited RB cells. A significant increase in phospho-H2AX, cleaved caspase-3, and cleaved PARP protein levels was observed in Y79 and Weri-Rb1 cells treated with Plk1 siRNA or BI-2536. These results suggest that Plk1 may be a rational target for RB therapy and encourages preclinical studies in animal models of RB. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4362.
Abstract P5-08-01: Oncology Clinicians’ Knowledge, Attitudes and Practices Regarding Fertility Preservation
Authors: SB Goldfarb, MN Dickler, MS McCabe, B Thom, X Jia, A Margolies, L Norton, C Hudis, E Basch, JF. Kelvin
Journal: Cancer Research (2010)

Abstract Background: Many breast cancer survivors of child-bearing age wish to become parents after therapy and are concerned about the possibility of treatment-induced infertility. Educating patients about the effects of therapy on fertility, early menopause, and fertility preservation options prior to treatment may optimize a survivor's quality of life after treatment. It is unclear whether oncologists feel qualified to discuss fertility issues with their patients, and if not, what barriers prevent such discussions. Methods: An IRB approved cross-sectional survey was developed at Memorial Sloan-Kettering Cancer Center (MSKCC) in order for clinicians to self-evaluate their knowledge, attitudes, and behaviors regarding fertility preservation. Survey items were derived from existing surveys in the literature and input from a multidisciplinary committee. The web-based survey was systematically administered to all MSKCC ambulatory clinicians. Repeated email reminders were sent to optimize responses. Results: 76 breast cancer clinicians at MSKCC and our regional network sites completed the survey between 2/9/09 and 2/25/09. Among respondents, there was widespread agreement (97% (70/72)) that patients should be informed of fertility preservation options, but fewer respondents (51% (37/72)) consistently discussed effects of treatment on fertility with their patients. Only 47% of clinicians (35/74) reported access to information about effects of treatment on fertility. Many physicians cited lack of training in fertility preservation, time constraints, and lack of referral information as barriers to educating patients. No significant difference existed in practice or knowledge between physicians who were practicing for ≤ 5 years vs ≥ 5 years. Conclusions: Physicians report that lack of education, resources and insufficient time hinder fertility preservation discussions with patients. Physicians might benefit from educational efforts regarding the effects of treatment on fertility and new fertility preservation techniques in order to effectively counsel their patients. Time limitations may be overcome by developing educational resources and collaborating with other clinical staff (e.g., nurses) to provide this vital information to patients. These findings are informing an institution-wide educational fertility program. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-08-01.
Genesis of the novel human-infecting influenza A(H10N8) virus and potential genetic diversity of the virus in poultry, China
Authors: W Qi, X Zhou, W Shi, L Huang, W Xia, D Liu, H Li, S Chen, F Lei, L Cao, J Wu, F He, W Song, Q Li, H Li, M Liao, M Liu
Journal: Eurosurveillance (2014)

Human infection with a novel influenza A(H10N8) virus was first described in China in December 2013. However, the origin and genetic diversity of this virus is still poorly understood. We performed a phylogenetic analysis and coalescent analysis of two viruses from the first case of influenza A(H10N8) (A/Jiangxi-Donghu/346-1/2013 and A/Jiangxi-Donghu/346-2/2013 and a novel A(H10N8) virus (A/chicken/Jiangxi/102/2013) isolated from a live poultry market that the patient had visited. The haemagglutinin (HA), neuraminidase (NA), PA subunit of the virus polymerase complex, nucleoprotein (NP), M and nonstructural protein (NS) genes of the three virus strains shared the same genetic origins. The origins of their HA and NA genes were similar: originally from wild birds to ducks, and then to chickens. The PA, NP, M, and NS genes were similar to those of chicken influenza A(H9N2) viruses. Coalescent analyses showed that the reassortment of these genes from A(H9N2) to A(H10N8) might have occurred at least twice. However, the PB1 and PB2 genes of the chicken A(H10N8) virus most likely originated from H7-like viruses of ducks, while those of the viruses from the case most likely stemmed from A(H9N2) viruses circulating in chickens. The oseltamivir-resistance mutation, R292K (R291K in A(H10N8) numbering) in the NA protein, occurred after four days of oseltamivir treatment. It seems that A(H10N8) viruses might have become established among poultry and their genetic diversity might be much higher than what we have observed.
SP0091 Gout Treatment: Does the Rate of Crystal Clearance Matter?
Authors: M. Doherty
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> An acute attack of gout causes extreme pain and tenderness that is recognised to be one of the most painful conditions to experience. Furthermore, subcutaneous tophi can cause visible deformity and local pain and inflammation, and clinically occult tophi and chronic subclinical crystal-induced inflammation may irreversibly damage joints and be a risk factor for cardiovascular disease. Therefore it is not surprising that ongoing gout associates with reduced quality of life. From a patients9 perspective gout it is something to get rid of as quickly as possible. Unfortunately, although involvement of patients in shared decision-making is recommended best practice, most patients are not asked the question "would you like us to get rid of your crystals as soon as we can or is it OK to take several years to do this?" When they are asked they inevitably vote for option one. The concept of speed of crystal clearance is relevant to two situations. Firstly, when urate-lowering therapy (ULT) is initiated and the practitioner must decide how low to reduce the patients serum uric acid (SUA) below the target of 360 μmol/L knowing that the lower the SUA the faster the velocity of crystal clearance and the sooner the patient is "cured" (i.e. no urate crystals). Increasingly the case is being made to maintain the SUA &lt;300 μmol/L, at least for the first year or so, to speed up removal of the crystals and their associated detrimental effects. The second situation is the question of when in the lifetime of the patient with gout should successful urate crystal clearance be encouraged by ULT? Again it is increasingly recommended that full patient education, including the option or ULT, should be discussed with the patient early around the time of first diagnosis. When fully informed, the majority of patients with gout opt for ULT rather than wait a number of years until the crystal load has increased even further. In both these situations it is apparent that the speed of crystal clearance does matter both in terms of medical logic and patient preference. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6154
Abstract 2452: Efficacy and toxicity of an anti-CD19 antibody drug conjugate
Authors: Chetana Rao, Chin Pan, Rangan Vangipuram, Mary Huber, Kavitha Vemuri, Alice Stevens, Colin Chong, Orville Cortez, Janette Sung, Dan Derwin, David Passmore, Qian Zhang, Sanjeev Gangwar, Pina Cardarelli, Shrikant Deshpande
Journal: Cancer Research (2010)

Abstract CD19 is an attractive target for immunotherapy. The expression of CD19 is restricted to B cells and follicular dendritic cells. In B cells, expression is initiated at the point of B lineage commitment and continues through the pre B and mature B cell differentiation. Expression is lost during the terminal differentiation of B cells to plasma cells. CD19 expression continues in B-lineage cells that have undergone neoplastic transformation, making it a useful marker in diagnosis and treatment of B cell derived lymphomas and leukemias, including non-Hodgkin's lymphoma (NHL), acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL). We have generated a fully human antibody to CD19 (MDX-1435) in transgenic mice for high binding affinity as well as the ability to rapidly internalize for drug delivery. The antibody was conjugated to a potent DNA alkylating agent related to Duocarmycin (MED-2460). This ADC (MDX-1206) shows anti-tumor activity in established Raji, Daudi and Ramos subcutaneous xenograft models at doses as low as 0.1 μmole/kg with no associated weight loss, or other overt toxicity. Efficacy was substantially superior to that of MDX-1435 and non-specific control antibody conjugates. In addition, MDX-1435 binds to cynomologus monkey CD19 with similar affinity and tissue distribution as in humans. The intravenous administration of two doses at 0.4 μmole/kg was well tolerated in cynomologus monkeys and did not result in overt clinical or histological signs of toxicity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2452.
Endocuff-assisted colonoscopy: a new accessory to improve adenoma detection rate? Technical aspects and first clinical experiences
Authors: Frank Lenze, Torsten Beyna, Philipp Lenz, Hauke Heinzow, Karin Hengst, Hansjoerg Ullerich
Journal: Endoscopy (2014)

<b>Background and study aims:</b> The Endocuff is a new colonoscopy accessory that has been designed to improve both the adenoma detection rate and endoscope tip control. <b>Patients and methods:</b> A total of 50 Endocuff-assisted colonoscopies were analyzed retrospectively with regard to safety, procedural success, and complications. <b>Results:</b> The cecal intubation rate was 98 %, and the mean intubation time was 6.0 minutes (95 % confidence interval 5.3 – 6.6 minutes). The ileal intubation rate was 76 %. In 30 % of patients, the Endocuff caused small, superficial, “scratch-like” mucosal lesions. In all other patients, no Endocuff-associated complications were observed. A total of 36 adenomas were detected in 50 patients. The adenoma detection rate was 34 %. <b>Conclusions:</b> Endocuff-assisted colonoscopy showed good procedural success rates in terms of cecal intubation rate and time, and a promising adenoma detection rate. Endocuff seems to improve endoscope tip control, especially during polypectomy. Endocuff may be a useful device for colorectal adenoma screening, and should be investigated in larger trials.
GROWTH DIFFERENTIATION FACTOR-15 (GDF-15) FOR PROGNOSTICATION OF OUTCOMES IN STABLE CORONARY ARTERY DISEASE: EXPERIENCES FROM THE STABILITY TRIAL
Authors: Lars Wallentin, Claes Held, Ralph Stewart, Andrzej Budaj, Christopher Cannon, Robert Harrington, Wolfgang Koenig, Susan Krug-Gourley, Philippe Steg, Elizabeth Tarka, Ollie Östlund, Harvey White, Agneta Siegbahn
Journal: Journal of the American College of Cardiology (2015)
FRI0136 Transition time to osteoporosis in patients with rheumatoid arthritis
Authors: H. J. Kim, J. Hwang, J. K. Ahn, E.-J. Park, H.-S. Cha, E.-M. Koh, J. Lee
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rheumatoid arthritis (RA) is an independent risk factor for osteoporosis. Although bone mineral density (BMD) testing is routinely performed in patients with RA, the optimal interval between BMD tests remains undetermined. <h3>Objectives</h3> The aim of this study was to evaluate the transition time to osteoporosis in RA patients with normal BMD and in those with osteopenia at baseline, and to estimate the optimal BMD testing interval. <h3>Methods</h3> We retrospectively analyzed 548 consecutive RA patients at a single tertiary hospital who underwent BMD testing on two or more occasions during October 1994 and December 2011. Patients were sorted into 5 groups; normal baseline BMD (T score, -1.00 or higher), mild osteopenia (T score, -1.01 to -1.49), moderate osteopenia (T score, -1.50 to -1.99), severe osteopenia (T score, -2.00 to -2.49) or osteoporosis (T score -2.50 or lower). The transition time to osteoporosis was defined as the estimated time for 10% of patients to make the transition to osteoporosis from normal BMD or from each subgroup of osteopenia. Risk factors for osteoporosis on initial BMD test were also assessed. <h3>Results</h3> Patients were mostly women (96.4%) and the mean age was 55.6 ± 10.6 years. The mean follow-up duration of RA was 8.8 ± 4.3 years. At initial visit, 9.1% of patients had a past history of steroid use for diseases other than RA. Rheumatoid factor was positive in 330 of 531 patients (62.1%) and anti-CCP antibodies in 138 of 206 patients (67%). The mean duration between the initial visit and the first BMD screening was 32.7 ± 40.2 months and the prevalence of osteoporosis was 31.7% at screening (95% confidence interval (CI) 27.6 to 36.1). Estimated transition time to osteoporosis was 72 months (95% CI 36 to 90) for patients with normal BMD, 62 months (95% CI 28 to 126) for patients with mild osteopenia, 34 months (95% CI 16 to 60) for patients with moderate osteopenia, and 17 months (95% CI 10 to 21) for patients with severe osteopenia. The adjusted odds ratio (OR) for osteoporosis at initial BMD testing was high for older age (OR 1.066, 95% CI 1.029 to 1.105, p &lt; 0.0001), past steroid use (OR 2.033, 95% CI 1.174 to 3.520, p = 0.0159), and current steroid use (OR 3.987, 95% CI 2.092 to 7.597, p &lt; 0.0001). <h3>Conclusions</h3> Our data indicate that osteoporosis would develop in less than 10% of RA patients within 6 years for patients with normal bone density, 5 years for patients with mild osteopenia, 2.5 years for patient with moderate osteopenia, and 1 year for patients with advanced osteopenia at baseline. Therefore, the interval for rescreening BMD testing should be adjusted based on the initial BMD result in patients with RA. <h3>Disclosure of Interest</h3> None Declared